#PRPH

ProPhase Labs Uplists from Pink Sheets to OTC Market ProPhase Labs (OTC: PRPH) announced that its common stock was approved and uplisted from the Pink Sheets to the OTC market on January 22, 2026. The company said it expects the coming weeks to be an important inflection point and highlighted continued momentum in its Crown Medical collections initiative. ProPhase said it will provide a near-term operational update on Crown Medical and a strategic update on its BE-Smart® Esophageal Cancer Test. Management reiterated focus on executing core businesses and strengthening the company’s financial position to drive long-term shareholder value.

1 month ago

#PRPH ProPhase Labs Uplists from Pink Sheets to OTC Market

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value ProPhase Labs (OTC: PRPH) provided an update on recent capital‑structure activity, stock volatility, and underlying asset value on January 5, 2026. Management said >$3.3 million of convertible debt principal has converted (from $3.8 million issued), leaving less than $500,000 unconverted. Conversions occurred at a floor price of ~$0.76 per share, which the company says is above current trading levels, reducing near‑term conversion selling risk. The company completed a 1‑for‑10 reverse split and moved from Nasdaq to the OTC market; management said these technical events, plus accelerated conversions, drove temporary selling pressure but did not change the intrinsic value of operating assets.Management emphasized debt reduction, a stronger balance sheet, and ongoing work on Crown Medical receivables, the BE‑Smart esophageal cancer diagnostic, and Nebula Genomics / DNA Complete.

2 months ago

#PRPH ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

Stock Master

@stockmaster70.bsky.social

2 months ago

📢 Stocks Trending NOW: #NKE #RIVN #PANW #CCL #FOLD #PRPH #FDX #FANG #SHOP #RDDT

0 0 0 0

ProPhase’s proposed ABL merger could mean cash payout for holders ProPhase Labs signs a non-binding LOI for a reverse merger with ABL, may pay a special dividend of up to $10M and carve out about $50M in receivables.

2 months ago

#PRPH ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.’ s control over ABL Diagnostics at this stage.. ABL Diagnostics informs its shareholders and the market that Advanced Biological Laboratories S.A., its controlling shareholder, and ProPhase Labs,...

2 months ago

#PRPH ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger

www.stocktitan.net/news/PRPH/abl-diagnostic...

1 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Leading Indicators, Tuesday December 9, 2025 – Crystal Equity Research

Small-cap stocks oversold with improving relative strength, Tue Dec 9th - #IZM #PRPH #BTM #TSE - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Leading Indicators, Monday December 1, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Mon Dec 1st - #TAOP #SGN #IWF #HUBC #DXST #VCIC #PRPH #JSPR #DYAI #CNEY #EVAC - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on December 1 ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature ProPhase Lab’s Chairman and CEO Ted Karkus. Attendees will gain an

3 months ago

#PRPH Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on December 1

www.stocktitan.net/news/PRPH/join-pro-phase...

0 0 0 0

ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET. ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important. Crown Medical Achieves Final Hurdle. Appointed Special Counsel to Launch Litigation Against Insurance Companies. First Settlement Completed.

3 months ago

#PRPH ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals ProPhase Labs (NASDAQ: PRPH) reminds shareholders of record as of Oct 20, 2025 to vote ahead of the Special Meeting on Nov 24, 2025 at 10:00 a.m. ET (in person at 273 Merrick Road, Lynbrook, NY).Shareholders should submit votes before the proxy deadline of 11:59 p.m. ET on Nov 23, 2025. The board recommends voting FOR all proposals to enable strategic initiatives and actions to maintain Nasdaq listing compliance; the definitive proxy is available on the SEC EDGAR site.

3 months ago

#PRPH ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it has engaged RedChip Companies (“RedChip”) to lead its investor relations efforts. “We are

4 months ago

#PRPH ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology ProPhase Labs (NASDAQ: PRPH) announced that a pivotal study validating the BE-Smart esophageal cancer proteomic test was accepted for publication in Clinical Gastroenterology and Hepatology on October 22, 2025. The study reported 100% sensitivity in a blinded cohort of 100 patients and strong discriminative performance (AUC 0.89–1.0) in independent test cohorts. ProPhase is advancing regulatory preparations, scaling laboratory capacity, and planning a phased commercial rollout beginning in 2026. Management cites a U.S. addressable market of roughly $7–$14 billion tied to ~7 million annual upper endoscopies for GERD and BE surveillance.

4 months ago

#PRPH ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

1 Billion Shares: ProPhase Labs Plans Major Expansion into Bitcoin Strategy and $15M Buyback Program ProPhase Labs announces special meeting to vote on increasing authorized shares to 1B, $15M share buyback, and crypto treasury strategy. Plans include potential $50M from Crown Medical initiative.

6 months ago

#PRPH ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

6 months ago

🚀 Exciting times for #PRPH! Despite a revenue miss, improved cost management and recent patent news spark optimism. Mixed technicals suggest potential support at $0.34. Consider a LONG position targeting $0.36 & $0.38 with caution. 📈 #FeetrAI #StockAnalysis

0 0 0 0

6 months ago

🚀 Exciting times for #PRPH! Trading at $0.3445, with short-term support and potential resistance ahead. Recent cost-cutting moves could boost profits. Consider a long position at $0.34, targeting $0.36 & $0.38. Stay alert to market trends! 📈 #StockMarket #FeetrAI

1 0 1 0

6 months ago

🚀 Exciting times for #PRPH! Trading at $0.3445, it's showing a short-term upward trend with potential resistance ahead. Despite a revenue miss, strategic moves could boost sentiment. Consider a LONG position: Entry at $0.34, target $0.36 & $0.38. Stop loss at $0.32. 📈 #FeetrAI

0 0 0 0

7 months ago

🚀 Exciting times for #PRPH! Despite a Q2 revenue miss, improved cost management hints at future profitability. Mixed technicals suggest cautious optimism: consider a LONG position at $0.34, targeting $0.36 & $0.38. Recent patent approval fuels long-term growth potential! 📈 #FeetrAI

0 0 0 0

7 months ago

🚀 Exciting times for #PRPH! With a strategic shift and patent approval, investor confidence is on the rise. Current price at $0.348 shows recovery, but watch that MACD! Consider going LONG with entry at $0.34, targeting $0.36 & $0.38. Stop loss at $0.33. 📈 #FeetrAI

0 0 0 0

7 months ago

🚨 FeetrAI Alert: #PRPH is in the spotlight! Despite a recent patent win, bearish signals dominate with prices below key SMAs and a negative MACD. Low volume and missed revenue add to the mix. Consider a SHORT at $0.335, targeting $0.320 & $0.310. Stay sharp! 📉 #Stocks #Trading

0 0 0 0

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

🚀 Exciting times for #PRPH! With a new U.S. patent approval, ProPhase Labs is poised for action. Trading just above its 8-day EMA, there's potential for a bullish move. Consider a long position at $0.33, targeting $0.35 & $0.37. Stay sharp, volatility ahead! 📈 #Stocks #FeetrAI

0 0 0 0

Nasdaq

7 months ago

ProPhase Labs Posts Narrower Q2 Loss | The Motley Fool

#PRPH #37977eda-6932-4d5f-bb51-c00839d31e91 #data-news

Origin | Interest | Match

0 0 0 0

ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025 ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart ™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a

7 months ago

#PRPH ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

7 months ago

🚀 Exciting times for #PRPH! Bullish vibes as ProPhase Labs partners with a pharma giant and advances antiviral drugs. Trading above 10-day SMA, strong volume, and room to grow! 📈 Consider a long position at $0.36, targeting $0.40 & $0.45. Stop loss: $0.34. #FeetrAI

0 0 0 0

ProPhase Labs Secures Game-Changing Patent for Early Cancer Detection with 95% Accuracy Rate Revolutionary biomarker test achieves 95% success rate in detecting esophageal cancer risk. Patent covers dual-compatibility diagnostic system. See clinical details.

7 months ago

#PRPH ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement ProPhase Labs (NASDAQ: PRPH) has announced a Special Meeting of Shareholders scheduled for August 29, 2025, where shareholders will vote on increasing the company's authorized shares to 1 billion. The Board unanimously recommends voting 'FOR' all proposals.The company aims to position itself for high-value structured transactions in the crypto treasury space, while simultaneously pursuing the collection of $50 million in Covid accounts receivables. ProPhase is also continuing the development of its BE-Smart™ esophageal cancer test and exploring strategic alternatives for Nebula Genomics, including a potential sale.

7 months ago

#PRPH ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

ProPhase Labs Faces Critical 6-Month Countdown to Avoid Nasdaq Delisting ProPhase Labs receives last-chance 180-day extension to meet Nasdaq's $1 minimum bid requirement. December deadline looms. See compliance plan details.

8 months ago

#PRPH ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0

ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer ProPhase Labs (NASDAQ: PRPH) has announced successful validation study results for its BE-Smart™ molecular diagnostic test, achieving over 95% technical success rate in detecting esophageal cancer through brush cytology samples. The test is uniquely designed to work with both forceps and brush biopsies, addressing a $10 billion target market. BE-Smart™ uses proprietary biomarkers to detect esophageal adenocarcinoma cancer (EAC), which has seen a 750% increase in incidence since the 1970s and has a 79% mortality rate. The company plans to launch the test clinically within 2-3 quarters. The test's compatibility with brush biopsies is significant as this method is gaining popularity due to lower costs and fewer complications compared to traditional forceps biopsies, which can miss up to 50% of Barrett's esophagus cases. With expanded payer coverage reaching over 73 million U.S. lives, BE-Smart™ positions itself as a comprehensive solution for esophageal disease surveillance.

8 months ago

#PRPH ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer

www.stocktitan.net/news/PRPH/pro-phase-labs...

0 0 0 0